

Rte: 00



Specimen ID: Control ID:

Phone:

Patient Details

DOB: Age(y/m/d): Gender: SSN: Patient ID:

Specimen Details Date collected: Date received: Date entered: Date reported:

Physician Details

Ordering: Referring: ID: NPI:

General Comments & Additional Information

Alternate Control Number:

Total Volume:

Alternate Patient ID: Fasting:

ng/mL

Acct #:

Ordered Items

Anti-Mullerian Hormone (AMH); Luteinizing Hormone (LH), S; FSH, Serum; Estradiol; Drawing Fee

TESTS RESULT FLAG UNITS REFERENCE INTERVAL

For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the samples.1 1. Kricka L. Interferences in Immunoassays - still a threat. Clin. Chem. 2000; 46: 1037-1038.

1.78

Reference Range:

Anti-Mullerian Hormone (AMH)

Females 36 - 40y: 0.42 - 8.34

Median 1.69

AMH concentrations of \geq = 1.06 ng/mL is correlated with a better response to ovarian stimulation, produced more retrievable oocytes and higher odds of live birth according to Gleicher et al. Fertility and Sterility. 2010: 94:2824-2827. The current AMH test method correlates with the study method with a slope of 0.94.

Females at risk of ovarian hyperstimulation syndrome or polycystic ovarian syndrome (PCOS) may exhibit elevated serum AMH concentrations. AMH levels from PCOS patients may be 2 to 5 fold higher than age-appropriate reference interval values.

Granulosa cell tumors of the ovary may secrete AMH along with other tumor markers. Elevated AMH is not specific for malignancy, and the assay should not be used exclusively to diagnose or exclude an AMH-secreting ovarian tumor.

Luteinizing Hormone (LH), S

7.4 LH mIU/mL Adult Female: Follicular phase 2.4 -12.6 Ovulation phase 14.0 -95.6 Luteal phase 1.0 -11.4

FSH, Serum

9.8 FSH mIU/mL Adult Female: 3.5 - 12.5Follicular phase

FINAL REPORT Date Issued: Page 1 of

Postmenopausal

7.7 -

58.5



Patient Report

Patient: Specimen ID: DOB: Patient ID: Control ID: Date collected:

| TESTS | RESULT | FLAG | UNITS | REFERENCE | INTERVAL | LAB |
|------------------------|--------|-------------|-----------|-----------|--------------|-----|
| | | Ovulatio | | | - 21.5 | |
| | | Luteal p | hase | | - 7.7 | |
| | | Postmeno | pausal | 25.8 | - 134.8 | |
| Estradiol | 27.0 | | / T | | | |
| ESCIACIOI | 27.0 | 7 d] + Domo | pg/mL | | | |
| | | Adult Fema | | 10 6 | 166.0 | |
| | | Ovulatio | ar phase | | | |
| | | | _ | | 211.0 | |
| | | Luteal p | | | | |
| | | | pausal | < 0.0 - | 34.7 | |
| | | Pregnancy | | 015 0 | > 1200 0 | |
| | | | | 215.0 - | | |
| | | Girls (1-1 | .u years) | 6.0 - | 27.0 | |
| Roche ECLIA methodolog | ДĀ | | | | | |
| | | | | | | |
| | | | | | | |